Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore.
Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
J Hosp Infect. 2024 Oct;152:126-137. doi: 10.1016/j.jhin.2024.08.002. Epub 2024 Aug 14.
Accurate effect estimates are needed to inform input parameters of health economic models. Central-line-associated bloodstream infections (CLABSIs) and catheter-related bloodstream infections (CRBSIs) are different definitions used for central-line bloodstream infections and may represent dissimilar patients, but previous meta-analyses did not differentiate between CLABSIs/CRBSIs.
To determine outcome effect estimates in CLABSI and CRBSI patients, compared to uninfected patients.
PubMed, Embase, and CINAHL were searched from January 2000 to March 2024 for full-text studies reporting all-cause mortality and/or hospital length of stay (LOS) in adult inpatients with and without CLABSI/CRBSI. Two investigators independently reviewed all potentially relevant studies and performed data extraction. Odds ratio for mortality and mean difference in LOS were pooled using random-effects models. Risk of study bias was assessed using ROBINS-E.
Thirty-six studies were included. Sixteen CLABSI and 12 CRBSI studies reported mortality. The mortality odds ratios of CLABSIs and CRBSIs, compared to uninfected patients, were 3.19 (95% CI: 2.44, 4.16; I = 49%) and 2.47 (95% CI: 1.51, 4.02; I = 82%), respectively. Twelve CLABSI and eight CRBSI studies reported hospital LOS; only three CLABSI studies and two CRBSI studies accounted for the time-dependent nature of CLABSIs/CRBSIs. The mean differences in LOS for CLABSIs and CRBSIs compared to uninfected patients were 16.14 days (95% CI: 9.27, 23.01; I = 91%) and 16.26 days (95% CI: 10.19, 22.33; I = 66%), respectively.
CLABSIs and CRBSIs increase mortality risk and hospital LOS. Few published studies accounted for the time-dependent nature of CLABSIs/CRBSIs, which can result in overestimation of excess hospital LOS.
为了为健康经济模型的输入参数提供准确的效果估计,需要准确的效果估计。中心静脉导管相关血流感染 (CLABSI) 和导管相关血流感染 (CRBSI) 是用于中心静脉导管血流感染的不同定义,可能代表不同的患者,但以前的荟萃分析没有区分 CLABSI/CRBSI。
确定与未感染患者相比,CLABSI 和 CRBSI 患者的结局效果估计。
从 2000 年 1 月至 2024 年 3 月,在 PubMed、Embase 和 CINAHL 上搜索全文研究,以报告有无 CLABSI/CRBSI 的成年住院患者的全因死亡率和/或住院时间 (LOS)。两名研究人员独立审查了所有潜在相关研究并进行了数据提取。使用随机效应模型汇总死亡率的优势比和 LOS 的平均差异。使用 ROBINS-E 评估研究偏倚的风险。
纳入了 36 项研究。16 项 CLABSI 和 12 项 CRBSI 研究报告了死亡率。与未感染患者相比,CLABSI 和 CRBSI 的死亡率优势比分别为 3.19 (95%CI:2.44,4.16;I=49%)和 2.47 (95%CI:1.51,4.02;I=82%)。12 项 CLABSI 和 8 项 CRBSI 研究报告了住院 LOS;只有 3 项 CLABSI 研究和 2 项 CRBSI 研究考虑了 CLABSIs/CRBSIs 的时间依赖性。与未感染患者相比,CLABSI 和 CRBSI 的 LOS 平均差异分别为 16.14 天 (95%CI:9.27,23.01;I=91%)和 16.26 天 (95%CI:10.19,22.33;I=66%)。
CLABSI 和 CRBSI 增加了死亡率风险和住院 LOS。少数已发表的研究考虑了 CLABSIs/CRBSIs 的时间依赖性,这可能导致对额外住院 LOS 的高估。